KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.85

Prophylactic Versus Reactive (PvR) Feeding in Patients Undergoing (Chemo)radiation in Head and Neck Cancers: Results of a Phase III Randomized Controlled Trial.

Sarbani Ghosh Laskar, Shwetabh Sinha, Meenakshi Jeeva, Meetakshi Gupta, Shreyasee Karmakar, Anuj Kumar, Samarpita Mohanty, Purabi Mahajan, Shivashankar Timmanpyati, Arun Balaji, Ashwini Budrukkar, Monali Swain, Faizalam Khan, Gouri Pantvaidya, Anuja Deshmukh, Deepa Nair, Devendra Chaukar, Prathamesh Pai, Shiva Thiagarajan, Richa Vaish, Vidisha Tuljapurkar, Pankaj Chaturvedi

Head Neck 47(12) 3301-3309

PMID40662454
PMCIDPMC12617468
DOI10.1002/hed.28244
发表日期2025-07-15
入排依据:The study is a Phase III randomized trial in human oncology, but it evaluates a non-drug intervention (prophylactic vs. reactive enteral feeding) and its primary endpoint is weight loss incidence, not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the inclusion criteria for a drug-containing intervention with a time-to-event endpoint.
摘要

摘要

BACKGROUND: Optimal feeding strategy (Prophylactic vs. Reactive) during Radiation Therapy (RT) for Head and Neck Cancers (HNC) remains to be established. METHODS: This phase III trial randomized (1:1) patients of HNC to prophylactic [nasogastric tube (NGT) placed at least 1 day before RT starting] versus reactive arm (NGT when required). The primary endpoint was the incidence of significant weight loss at 6 months. Secondary endpoints were weight changes, tube duration, dependence, and compliance. RESULTS: Due to high denial rates, the trial was prematurely closed. Eighty-four patients (40-prophylactic, 44-reactive) were analyzed intention-to-treat. Seventeen patients (39%) required a reactive tube insertion. The proportion of patients with significant weight loss at 6 months in the prophylactic versus reactive arms was 13 (32.5%) versus 10 (15.9%), p = 0.44. The median tube duration was 56 days (IQR: 16.5-91) versus 47 days (IQR: 24-59), p = 0.255. CONCLUSION: Our limited analysis found that a reactive NGT should be considered for most HNC patients undergoing RT. TRIAL REGISTRATION: Clinical trials registry of India: CTRI/2020/01/023049.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

FIGURE 3

FIGURE 3 (a) Progression free survival and 3, (b) Overall Survival in the prophylactic and reactive cohorts respectively. 2‐year PFS: 64% (95% CI: 46–79) versus 57.9% (95% CI: 44–76), p = 0.9; and 2‐year OS: 66% (95% CI: 52–84) versus 59% (95% CI: 45–76), p = 0.64. [Color figure can be viewed at wileyonlinelibrary.com ]

Progression_free_survival

Progression free survival

FIGURE 3 · Panel Progression_free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Progression_free_survival 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:short span
查看结果
Overall_survival

Overall survival

FIGURE 3 · Panel Overall_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_survival 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Consort diagram depicting numbers screened, reasons for screen failure, number of patients accrued, withdrawn from the study and the number of patients for whom data was available at each follow‐up visit.
非 KM Figure
FIGURE 2FIGURE 2 Distribution of median body weight (on y axis in kgs) of patients in both the study arms at baseline (prior to radiotherapy starting), during RT, at conclusion of RT, 1st and 2nd follow‐up. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure
FIGURE 4FIGURE 4 Forest plot for factors impacting significant weight loss at 6 months (Subgroup analysis). [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure